Prudential Financial Inc. raised its position in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 1.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 109,192 shares of the biotechnology company’s stock after buying an additional 1,060 shares during the period. Prudential Financial Inc. owned about 0.16% of Momenta Pharmaceuticals worth $1,458,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of MNTA. JPMorgan Chase & Co. increased its stake in shares of Momenta Pharmaceuticals by 65.1% in the first quarter. JPMorgan Chase & Co. now owns 636,744 shares of the biotechnology company’s stock valued at $8,500,000 after buying an additional 251,159 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Momenta Pharmaceuticals by 3.0% in the first quarter. Envestnet Asset Management Inc. now owns 14,275 shares of the biotechnology company’s stock valued at $191,000 after buying an additional 411 shares in the last quarter. Mason Street Advisors LLC increased its stake in shares of Momenta Pharmaceuticals by 8.3% in the first quarter. Mason Street Advisors LLC now owns 15,122 shares of the biotechnology company’s stock valued at $202,000 after buying an additional 1,154 shares in the last quarter. Marcus Capital LLC purchased a new stake in shares of Momenta Pharmaceuticals during the first quarter valued at approximately $1,319,000. Finally, Alambic Investment Management L.P. increased its stake in shares of Momenta Pharmaceuticals by 60.6% in the first quarter. Alambic Investment Management L.P. now owns 51,702 shares of the biotechnology company’s stock valued at $690,000 after buying an additional 19,500 shares in the last quarter. Hedge funds and other institutional investors own 86.62% of the company’s stock.

Momenta Pharmaceuticals, Inc. (MNTA) traded up 1.55% on Friday, hitting $16.40. The company had a trading volume of 573,993 shares. The firm’s market capitalization is $1.20 billion. Momenta Pharmaceuticals, Inc. has a 12-month low of $10.50 and a 12-month high of $19.90. The firm has a 50-day moving average price of $16.96 and a 200-day moving average price of $15.62.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). The business had revenue of $23.57 million for the quarter, compared to analyst estimates of $24.64 million. Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. Momenta Pharmaceuticals’s revenue was down 10.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.31) earnings per share. On average, equities research analysts anticipate that Momenta Pharmaceuticals, Inc. will post ($1.44) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Prudential Financial Inc. Has $1.46 Million Stake in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/04/prudential-financial-inc-acquires-1060-shares-of-momenta-pharmaceuticals-inc-nasdaqmnta-updated-updated-updated.html.

Several brokerages have recently commented on MNTA. Stifel Nicolaus restated a “buy” rating and issued a $26.00 target price on shares of Momenta Pharmaceuticals in a research note on Thursday. Maxim Group set a $6.00 target price on shares of Momenta Pharmaceuticals and gave the company a “sell” rating in a research note on Thursday. Zacks Investment Research downgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday. BidaskClub downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 6th. Finally, Aegis restated a “hold” rating and issued a $17.00 target price on shares of Momenta Pharmaceuticals in a research note on Wednesday, May 3rd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. Momenta Pharmaceuticals currently has an average rating of “Hold” and an average target price of $16.89.

In related news, President Craig A. Wheeler sold 4,116 shares of the firm’s stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $15.83, for a total value of $65,156.28. Following the sale, the president now directly owns 281,919 shares of the company’s stock, valued at $4,462,777.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 8,579 shares of company stock worth $135,225 over the last ninety days. 4.40% of the stock is currently owned by insiders.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.